What are the potential mechanisms for the observed benefits on the cardio-renal axis? 06:15

The guidelines recommend using empagliflozin in patients with diabetes and CVD 09:21

Comparing the EMPA-REG OUTCOME and CANVAS study; results with empagliflozin and canagliflozin 11:12

Educational information

The educational objectives of this symposium were to:

Summarise the epidemiology and pathophysiology of patients at increased cardiovascular risk and diabetes

Identify key components of renal glucose handling and the contribution of the kidney to glucose homeostasis

Describe the effect of multiple interventions that currently are deployed for T2D on cardiovascular safety and the currently unmet need on impacting cardiovascular outcomes

Explain, based on scientific evidence, the effects that SGLT2 inhibiting agents may have on cardiometabolic markers, including lipids, weight gain, risk of hypoglycemia, HbA1c, glucose levels, related markers and cardiovascular outcomes

Discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multi-risk patients

Faculty

Naveed Sattar, MD is Professor of Metabolic Medicine, OCDEM, University of Oxford. He is an academic (active clinically) experienced in biomarker studies/trials investigating the causes, prevention and management of diabetes, obesity and heart disease. He has authored or co-authored over 650 published papers, has received several national and international prizes for his research, and is in the top 1% of cited clinical academics in the world according to the Thomson Reuters 2016 Highly Cited Researcher list.

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

This symposum was supported by an unrestricted educational grants provided by Boehringer-Ingelheim/Lilly